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H. Joachim DeegBone marrow (BM) disorders, which would qualify
as what we now call myelodysplastic syndromes
(MDS), have been recognized for at least a century
[1]. However, it was not until the 1970s and early
1980s that Bennett et al. presented a classification sys-
tem [2]. This French-American-British (FAB) classifi-
cation system proved to be very helpful for clinical
prognostication and treatment decisions. Themore re-
cent development of the International Prognostic
Scoring System (IPSS) by Greenberg et al. [3], and
the subsequent proposal by theWorld Health Organi-
zation (WHO) [4,5], reflect our improvingunderstand-
ing of various parameters that have an impact on the
disease course. The addition of red blood cell transfu-
sion dependence to the WHO prognostic scoring sys-
tem (WPSS) may have further improved our ability to
predict patient risk and prognosis [6].
The recognition of MDS as a clonal disorder of
hematopoietic stem/precursor cells identified it as adis-
ease that should be treatable and potentially curable by
hematopoietic cell transplantation (HCT) [7]. This
indeed proved to be the case, and by now some patients
have been followed for more than 25 years, apparently
cured of their disease [8]. But, this modality of treat-
ment has been applied to only a small proportion of pa-
tients, because of concerns about the toxicity associated
withHCT in patients whomight have a life expectancy
of several years with conservative management; be-
cause of age, a most relevant factor, since the median
age at diagnosis of MDS is in the eighth decade of
life; or because of the lack of a suitable donor [9,10].
Various developments in the field of HCT have ex-
panded the indications for transplantation and have re-
duced the morbidity and toxicity associated with the
procedure, however [11-13].
Concurrently, studies aimed at characterizing at
the cellular and molecular levels the pathophysiologyFredHutchinson Cancer Research Center, Seattle, Wash-
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ment of nontransplantation therapies. The FDA’s
approval of 3 drugs (5 azacitidine, 5 aza-2’deoxyazaci-
tidine, and lenalidomide) to treat MDS has led to
extensive studies on the indications, efficacy, and
limitations of these drugs [14-18]. Other treatment
modalities, such as immunosuppression and cytokine
blockade, have shown promise in subgroups of patients
[19-22]. Those studies in turn have stimulated interest
in further defining various aspects of the pathogenesis
and pathophysiology of MDS.
At the same time, a proportion of patients who are
being treated successfully with chemotherapy or radi-
ation for various diagnoses will develop MDS, appar-
ently secondary to the effects of cytotoxic therapy
[23-25]. These treatment-related cases of MDS tend
to behave more aggressively and generally are more
difficult to treat than de novo MDS.
In this symposium, 3 experts provide an update on
transplantation and nontransplantation therapies for
MDSandour current understanding of secondaryMDS.ACKNOWLEDGMENTS
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